PIMJETMI® (pimicotinib) Developed by Abbisko Therapeutics and Licensed by Merck KGaA, Darmstadt, Germany Receive U.S. FDA Approval for TGCTPRNewsWire • Wednesday
Earnings Preview: Merck KGaA (MKKGY) Q3 Earnings Expected to DeclineZacks Investment Research • 11/05/26
Evinova Launches Strategic Partnership with Merck KGaA, Darmstadt, Germany to Define the Future of Clinical DevelopmentBusiness Wire • 07/29/26
Merck KGaA (MKKGY) Moves to Strong Buy: Rationale Behind the UpgradeZacks Investment Research • 07/23/26
Merck KGaA (MKKGY) Soars 5.3%: Is Further Upside Left in the Stock?Zacks Investment Research • 06/26/26